Dendreon Halted And Reopened After The Stock Spikes Triggering Circuit Breakers

provenge dendreon

Cancer drug developer Dendreon announced Q4 revenue early.  And revenue was good.

Gross product revenue jumped 230% year-over-year to $82 million.  This also represents a 25% increase from Q3.

“We are pleased with the progress we have made in the launch of PROVENGE, which — based on its first full year of revenues — places it as one of the top 10 product launches in oncology,” said CEO Mitchell  Gold, MD.

The stock is up nearly 40% this morning.

This according to CNBC.  More details to follow as the story develops.

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at